Oromandibular dystonia …

Joseph Jankovic MD

Movement Disorders

Updated 03.01.2024
Released 12.01.1998
Expires For CME 03.01.2027

Oromandibular dystonia

Author: Joseph Jankovic MD

See Contributor Disclosures

Oromandibular dystonia

In This Article

Quick Link

Introduction

Overview

Oromandibular dystonia is a form of focal dystonia manifested by jaw closure often associated with clenching of the jaws and grinding of teeth (bruxism) and may lead to temporal-mandibular joint syndrome (16; 39). Other forms of oromandibular dystonia include jaw opening and deviation. The author discusses the cause of this dystonia and its management, focusing on botulinum toxin injection, which is the treatment of choice.

Key points

	• Oromandibular dystonia is a form of focal dystonia involving the jaw, tongue, and lower face.
	• There are four types of oromandibular dystonia: jaw closure (associated with trismus and bruxism), jaw opening, jaw deviation, and mixed.
	• Botulinum toxin injection is considered the first line of treatment for oromandibular dystonia.

Historical note and terminology

Horatio Wood, a United States neurologist, described involuntary facial and oromandibular movements in 1887, 23 years before the French neurologist Henry Meige reported a series of patients who exhibited dystonic contractions of facial and neck muscles (74; 64). The term “dystonia” was coined in 1911 by Oppenheim, a German clinician. Although the term "torsion dystonia" has been used in the literature, not every patient with dystonia has "torsion," and, hence, the simple term “dystonia” is currently preferred. Discoveries of genetic markers in some primary and secondary forms of dystonia have contributed to the development of newer nosology and classification of dystonia (28). When no etiology can be identified, the dystonia is referred to as primary dystonia. Primary dystonia can be either sporadic or inherited and is not associated with any cognitive, pyramidal, cerebellar, or sensory abnormalities. The term "dystonia plus" is used when an associated neurologic abnormality exists, such as parkinsonism, dementia, corticospinal tract signs, and other neurologic disturbances besides dystonia. By definition, all cases of "dystonia plus" are secondary, although the etiology (eg, neuroleptics, Wilson disease, neuroacanthocytosis, trauma) may not always be obvious.

Clinical manifestations

Presentation and course

Dystonia (Meige syndrome) helped by botulinum toxin

This patient with cranial dystonia manifested by incapacitating blepharospasm and oromandibular dystonia markedly improved with botulinum toxin injections into the affected facial and jaw muscles. She has continued to do well with...
Dystonia (oromandibular) worse after dental procedure helped by botulinum toxin

This woman with an 8-month history of oromandibular dystonia had a dental procedure, following which her dystonia progressed to cranial dystonia. The dystonia markedly improved after injection of botulinum toxin into affected faci...

Oromandibular dystonia is a focal dystonia manifested by involuntary muscle contractions producing repetitive patterned mouth, jaw, and tongue movements (49; 12; 16; 33; 82). Many patients with oromandibular dystonia initially present with blepharospasm, and blepharospasm often spreads to the oromandibular region, leading to oromandibular dystonia (07). Patients with oromandibular dystonia have difficulty chewing, eating, and speaking because of an inability to open or close their jaw. In addition, there is often lingual dystonia, activated by eating, which causes the tongue to push the food out of the mouth. Because of the eating difficulties, some patients lose weight. In addition to the dysarthria, dysphagia, dysphonia, and respiratory difficulties, many patients with bulbar dystonia display involuntary vocalizations, including humming, grunting, belching, and gasping. In a retrospective review of 240 patients with oromandibular dystonia, the mean age at onset was 51.6 years old, with a 2:1 female predominance and family history of dystonia in six patients (2.5%) (91). Jaw-opening type of oromandibular dystonia was found in 149 patients (62.1%); 48 (20.0%) had the jaw-closing type, 43 (17.9%) had a mixed form of oromandibular dystonia, and lingual dystonia was also present in 64 patients (26.7%).

Oromandibular dystonia may cause a jaw closure with clenching, trismus, and bruxism (60; 110; 99; 13; 61; 105; 72). In a study of 2020 patients with oromandibular dystonia, the typical age at onset was in the 50s, and 70% of cases were female; the perioral musculature was involved in 85%, jaw in 61%, and tongue in 17% (86). Most of the patients were females, and many had associated depression and anxiety. Bruxism, also referred to as teeth-clenching or teeth-grinding, may be a manifestation of oromandibular dystonia or abnormal masticatory muscle activity as part of nocturnal oral parafunction or nocturnal bruxism (see also MedLink article on sleep bruxism by Gerstner). The involuntary movement disorder, whether diurnal or nocturnal, results in chronic jaw clenching (trismus) and tooth grinding (bruxism) (61; 105). Although the cause of bruxism is probably multifactorial, the disorder is often associated with oromandibular dystonia and other neurologic disorders such neuroacanthocytosis, Huntington disease, Tourette syndrome, autism, Rett syndrome, dementing disorders (58), basal ganglia infarcts, and brainstem lesions, as well as jaw injury or surgery and drugs such as the dopamine receptor blocking drugs (neuroleptics), serotonin uptake inhibitors, CNS stimulants, and ecstasy (03; 26). Similar to other dystonias, many patients with bruxism associated with oromandibular dystonia have noted that various maneuvers (sensory tricks) and dental prosthetic devices relieve their jaw spasms.

In addition, involuntary jaw closure, jaw opening, or jaw deviation dystonia may occur and may interfere with speaking and chewing. In contrast to jaw-closing dystonia, jaw-opening oromandibular dystonia tends to be associated with dystonia in other body regions (90). Many patients have noted that various alleviating maneuvers (sensory tricks) and dental prosthetic devices relieve their jaw spasms, particularly jaw closure dystonia (31). In some cases, the involuntary movements occur only during a specific task, such as speaking or reciting prayers (42). Oromandibular dystonia may follow jaw injury or surgery and may be complicated by secondary dental wear and temporal-mandibular joint syndrome (81; 94). In one study of 53 patients with oromandibular dystonia, 90% screened positive for temporal-mandibular joint syndrome (94). Besides primary or peripherally induced dystonia, oromandibular dystonia may be associated with or secondary to a variety of neurodegenerative disorders such as neuroacanthocytosis, Huntington disease (47), basal ganglia infarcts (96), and brainstem lesions (23). Oromandibular dystonia should be differentiated from hemifacial or hemimasticatory spasm, tetany, tetanus, trismus, and mechanical disorder of the jaw or the temporomandibular joint (103; 45; 109; 98; 101; 87; 111). Another condition associated with involuntary jaw movements is Tourette syndrome in which dystonic oromandibular tics may be the main involuntary movements but are usually accompanied by other motor and phonic tics (04).

Prognosis and complications

Although it is difficult to predict the future course of oromandibular dystonia, in most cases, the dystonia remains confined to the oromandibular region. In many cases, however, the dystonia spreads to adjacent structures, causing blepharospasm, cervical dystonia, and other forms of dystonia. Longstanding jaw-closure dystonia may result in secondary temporomandibular joint syndrome.

Clinical vignette

A 61-year-old woman underwent a series of dental procedures, including gingivectomy and braces for six months. Afterwards, she had cosmetic filling of her maxillary teeth, followed by the placement of three separate bridges. On the same day of this last procedure, she noticed abnormal jaw movements that caused displacement of the left bridge. Since that time, she has been unable to wear her lower dentures. Her mouth and jaw movements worsened gradually over the next 16 years. The patient also had mouth soreness on wearing her dentures and had difficulty in speaking clearly due to the painful spasms. Four years prior to our evaluation, her movements occurred only while wearing dentures and completely resolved within 30 minutes after their removal. The movements could be relieved by sensory tricks such as touching her tongue to the top of her mouth, biting her lips, and swallowing. The patient was seen for the last 16 years by various dentists and physicians without any medications or a working diagnosis.

Examination revealed repetitive deviation of the mandible to the left, particularly when speaking and chewing. She had bilateral masseter spasms and considerable difficulty in moving her jaw to the right, particularly when the upper dentures were in place. She was injected with 195 units of botulinum toxin-A over two sessions, and experienced dramatic relief of her symptoms (grade 4 improvement) for about four months; during which time she was able to wear her dentures without any discomfort.

Biological basis

Etiology and pathogenesis

Dystonia is either a symptom of an underlying disorder or a specific disease entity (49; 02). When dystonia occurs as an isolated neurologic disorder without any evidence of cognitive abnormalities, seizures, weakness, sensory, or cerebellar deficit and without other movement disorders, it is classified as primary dystonia. Primary dystonia can be either sporadic or inherited. Secondary dystonias are caused by a specific structural, metabolic, toxic, or other etiology. Secondary dystonia may occur after a specific event, such as head trauma, encephalitis, stroke, brain surgery, or exposure to certain drugs, and in association with a variety of systemic and neurodegenerative disorders (80; 43). Virtually any metabolic or structural lesion of the brain, particularly if it involves the putamen, other basal ganglia, rostral brainstem, and upper cervical lesions, may result in cranial, including oromandibular, dystonia (37). Although genetic predisposition has been suggested to play a role in some cases of secondary dystonia (30), the DYT1 gene mutation is rarely associated with oromandibular dystonia (14). GTP-cyclohydrolase 1 (GCH1) gene mutation was reported in a 49-year-old man with oromandibular dystonia (92).

In contrast, DYT6 dystonia, caused by mutations in the THAP1 gene on chromosome 8p21-q22, in addition to the clinical phenotype of DYT1, also involves the head, jaw, neck, and larynx; it is often associated with oromandibular dystonia (32). The product of the THAP1 gene has been found to be involved with DNA binding and in regulation of endothelial cell proliferation (11). The typical onset is cranial and brachial rather than cervical, with dystonia gradually becoming generalized in all (15). The oldest age at onset was 49 years. Childhood-onset spasmodic dysphonia progressing to generalized dystonia is another presentation of DYT6 (24). In addition to Amish-Mennonite families, DYT6 has also been documented in British patients and other populations (40). In an American series, THAP1 heterozygous mutations were identified in 9 of 36 (25%) DYT1-negative families with early-onset, non-focal primary dystonia (15).

Of the secondary dystonias, Wilson disease and drug-induced (tardive) dystonia are particularly important to recognize because early treatment can result in a complete, or near complete, abolishment of the involuntary movement (93; 95; 108). Oromandibular dystonia may also be a manifestation of levodopa-related dyskinesia (102). Besides central etiologies, which presumably account for the vast majority of dystonias, peripherally induced dystonia caused by an injury is being increasingly recognized as an important cause of oromandibular dystonia (81). Oromandibular dystonia may be also associated with or secondary to a variety of brainstem lesions and neurodegenerative disorders such as neuroacanthocytosis, Huntington disease (97; 47), and rapid-onset dystonia-parkinsonism associated with mutation in the Na/K-ATPase alpha3 subunit (ATP1A3) (51). Bruxism, a form of jaw closure oromandibular dystonia, has also been associated with the use of drugs such as ecstasy and serotonin uptake inhibitors such as venlafaxine (03).

Pathophysiology of dystonia. The pathophysiology of dystonia is not well understood, but progress has been made as a result of novel neurophysiologic and imaging techniques (06; 21; 36; 65). Excessive cocontraction of antagonist muscles, one of the physiological hallmarks of dystonia, is apparently produced by abnormal synchronization of presynaptic inputs to antagonist motor neuron pools (29). Abnormalities in early and late long-latency reflex responses have been found in focal dystonia and can be influenced by botulinum toxin injections, suggesting the involvement of peripheral mechanisms (68). Several investigators have demonstrated increased amplitude and duration of the R1 and R2 blink responses, not only in patients with blepharospasm but also in patients with other dystonias, including oromandibular dystonia (37). These findings have been interpreted as being indicative of enhanced excitatory drive to the rostral brainstem or reduced spinal and brainstem inhibition. Abnormal processing of muscle spindle input has been suggested as an important element in the pathophysiology of dystonia. The frequent co-existence of blepharospasm and oromadibular dystonia supports the notion of a common pathophysiologic mechanism for this cranial dystonia (85).

The involvement of basal ganglia in dystonia is also supported by the finding of reduced glucose metabolism, as demonstrated by PET scans, in the basal ganglia, the frontal projection field of the mediodorsal thalamic nucleus, and in the frontal cortex of patients with primary dystonia (53). Blood flow PET and activation studies suggest that the chief alteration in primary dystonia is overactivity of the planning (rostral) portion of the cortical supplementary motor area, prefrontal area, and the caudate nucleus, whereas the motor executive (caudal) portion of the supplementary motor area and the motor cortex are underactive (19). These findings have been interpreted as evidence of thalamo-frontal disinhibition and abnormal central sensorimotor processing in dystonia (35). In addition to cortical abnormalities, PET and neurophysiologic studies have demonstrated altered function of subcortical structures. Eidelberg and colleagues demonstrated two patterns of metabolic abnormality in patients with dystonia: (1) increased activity in the lentiform nuclei, cerebellum, and supplementary motor area, found in dystonic patients without evident dystonia during sleep (movement-free) and (2) increased metabolic activity in the midbrain, cerebellum, and thalamus, found only in patients who exhibited dystonia at rest while awake (movement-related) (25). Various neurophysiologic and imaging studies provide additional support for the observation that in dystonia there is reduced pallidal inhibition of the thalamus that may explain the overactivity of medial and prefrontal cortical areas and underactivity of the primary motor cortex (06). Pallidal overactivity has been demonstrated in patients with dystonia by microelectrode recordings, and pallidotomy appears to be an effective procedure for patients with dystonia (71; 107).

Pathoanatomy and biochemistry. Although in most patients with dystonia, no specific abnormality can be identified by neuroimaging or autopsy studies, there is convincing evidence supporting a central origin (basal ganglia, brainstem, or both) for this movement disorder. Lesions, particularly in the putamen and globus pallidum internum, have been associated with dystonia (76; 08; 17; 57). Among 240 patients with lesions in the basal ganglia, dystonia was observed in 36% (08). In an anatomic-clinical study using 3-dimensional MRI, "dystonic spasms" were associated with a lesion in the striatopallidal complex, whereas "myoclonic dystonia" was associated with lesions in the thalamus, particularly ventral intermediate and ventral caudal nuclei (63). In another study, using 3-dimensional T1-weighted MRI, striatopallidal dystonia was attributed to lesions within the sensorimotor part of the striatopallidal complex, and thalamic dystonia was associated with lesions in the centromedian or the ventral intermediate nuclei (57).

Imaging studies do not usually show any specific abnormalities, but T2 values on high-field MRI have been found to be significantly higher in the putamen and pallidum of patients with cervical dystonia, as compared to age-matched controls (84). A 10% enlargement of the putamen was found in another study of patients with focal dystonia (09). Although this finding probably reflects a response to the dystonia, it could also indicate early gliosis in the lentiform nucleus.

Only a mild reduction in striatal [18F]dopa uptake was demonstrated in some patients with familial primary dystonia and in dopa-responsive dystonia (70; 77). Dopamine receptor binding, measured by C11 spiperone PET scan, appears normal or slightly increased in the contralateral striatum in patients with idiopathic focal dystonia (62). In contrast to that study, Perlmutter and colleagues found about a 30% reduction in D2 receptor density, as estimated by PET scans of patients with hand dystonia using [18F]spiperone (75).

Only limited information is available on biochemical analyses of the brains of patients with dystonia. The observation that manipulation of the dopaminergic system can produce or ameliorate dystonia has provided evidence for the role of dopamine in the pathogenesis of primary dystonia. Although complex 1 mitochondrial defect has been suggested in idiopathic dystonia (05), a subsequent study demonstrated such defect only in the platelets of patients with focal and not generalized dystonia (83).

A major advance in the understanding of autosomal dystonia has been the identification of a gene mutation (DYT1) in the q32-34 region of chromosome 9 in a large, non-Jewish kindred (56; 59). The mutation consists of a three base-pair deletion in a gene coding for a novel ATP-binding protein in the 9q34 locus, termed “torsinA” (73). In addition to the DYT1 dystonia, several other genetic forms of dystonia have been identified. Mutations in the GTP-cyclohydrolase 1 gene on chromosome 14 (41) have been associated with dopa-responsive dystonia. This form of dystonia, however, is rarely manifested by oromandibular dystonia. Of the 13 types of primary genetic dystonia for which a gene marker or actual gene mutation has been identified, only DYT 7 (mapped to chromosome 18p) and DYT 13 (mapped to chromosome 1p36.13-36.22) dystonias have been associated with cranial, including oromandibular, dystonia (55; 106).

Differential diagnosis

Table 1 lists the causes of dystonia with emphasis on the causes of oromandibular dystonia.

Table 1. Etiology of Blepharospasm and Oromandibular Dystonia

I. Primary dystonia
	A. Sporadic
	B. Inherited
		• Classic (Oppenheim) dystonia (DYT1-9q34; ATP-binding protein, TorsinA) • Childhood- and adult-onset cranial-cervical-limb dystonia (DYT6-8p21-22) • Adult-onset cervical and other focal dystonia (DYT7-18p) • Adult-onset cranial-cervical dystonia (DYT13-1p36.13-36.32)
II. Associated with neurodegenerative disorders
	A. Primarily sporadic
		• Parkinson disease • Progressive supranuclear palsy • Multiple system atrophy • Multiple sclerosis • Central pontine myelinolysis • Juvenile Parkinsonism-Dystonia • Progressive pallidal degeneration • Intraneuronal inclusion disease • Infantile bilateral striatal necrosis • Familial basal ganglia calcifications
	B. Primarily inherited
		1. Dystonia-plus syndromes
			• Atypical autosomal dominant dystonia (not DYT1 gene) • Myoclonic dystonia • Dopa-responsive dystonia (DYT5-GTP cyclohydrolase I 14q22.1) • Rapid-onset dystonia-parkinsonism • Early-onset parkinsonism with dystonia • X-linked dystonia-parkinsonism or Lubag • Paroxysmal dystonia-choreoathetosis • Wilson disease • Tourette syndrome • Huntington disease • Hallervorden-Spatz disease • Machado-Joseph disease • Ataxia telangiectasia • Neuroacanthocytosis • Olivopontocerebellar atrophy • Hereditary spastic paraplegia with dystonia • Fragile-X syndrome
III. Associated with metabolic disorders
	A. Amino acid disorders
		• Glutaric acidemia • Methylmalonic acidemia • Homocystinuria • Hartnup disease • Tyrosinosis
	B. Lipid disorders
		• Metachromatic leukodystrophy • Ceroid lipofuscinosis • Dystonic lipidosis ("sea blue" histiocytosis) gangliosidoses • Hexosaminidase A and B deficiency
	C. Miscellaneous metabolic disorders
		• Mitochondrial encephalopathies • Leigh disease, Leber disease • Lesch-Nyhan syndrome • Triosephosphate isomerase deficiency • Vitamin E deficiency • Biopterin deficiency • Pseudohypoparathyroidism
IV. Due to a specific cause
		• Perinatal cerebral injury and kernicterus: athetoid cerebral palsy, delayed onset dystonia • Infection: viral encephalitis, encephalitis lethargica, Reye syndrome, subacute sclerosing panencephalitis, Jakob-Creutzfeldt disease, AIDS • Other: tuberculosis, syphilis, tetanus • Collagen vascular disorder • Paraneoplastic brainstem encephalitis • Cerebral vascular or ischemic injury • Brain tumor • Arteriovenous malformation • Head trauma and brain surgery • Peripheral trauma • Toxins: manganese , carbon monoxide, carbon disulphide, methanol, disulfiram, wasp sting • Drugs: levodopa, bromocriptine, antipsychotics, metoclopramide, fenfluramine, flecainide, ergot drugs, anticonvulsants, certain calcium channel blockers
V. Due to an ophthalmologic cause
	A. Reflex blepharospasm
		• Blepharitis, conjunctivitis, "dry eye syndrome," keratitis, iritis, uveitis • Albinism, achromatopsia, maculopathies • Lesions in the nondominant temporoparietal lobe (Fisher sign)
	B. Peripherally induced
		• Hemifacial spasm • Tic convulsif • Bell palsy • Aberrant facial regeneration with facial synkinesis • Hemimasticatory spasm • Facial myokymia • Schwartz-Jampel syndrome • Amyloidosis • Oculomasticatory myorhythmia (Whipple disease)

Oromandibular dystonia is occasionally confused with other facial movement disorders, such as hemifacial spasm (109), facial tics, myokymia, myorhythmia, hemimasticatory spasm, and aberrant regeneration with synkinesis after Bell palsy. Hemifacial spasm is characterized by initially progressive, involuntary, irregular, clonic, or tonic movements of muscles innervated by the seventh (facial) cranial nerve on one side of the face. It often initially involves the orbicularis oculi muscle, followed by gradual spread to other parts of the face. Usually without any identifiable etiology, this peripheral movement disorder has been most frequently attributed to compression of the facial nerve at the root exit zone by an ectopic anatomical or pathological structure, resulting in "ephaptic transmission." Rare cases of bilateral hemifacial spasm have been reported (97). When hemifacial spasm coexists with trigeminal neuralgia, suggesting that both facial and trigeminal nerves are compromised, it is referred to as "tic convulsif." Hemimasticatory spasm is a rare disorder in which painful muscle contractions, frequently associated with hemifacial atrophy, affect the jaw-closing muscles innervated by the trigeminal nerve (masseter). Bilateral hemimasticatory spasm, which would most closely resemble jaw-closing dystonia, has not been reported. Hemimasticatory spasm has been attributed to an abnormal trigeminal hyperexcitability likely induced by a demyelinating lesion of the trigeminal nerve (27).

Management

Oromandibular dystonia rarely improves with medications, although some patients report modest benefit with anticholinergic drugs (eg, trihexyphenidyl), baclofen, benzodiazepines, and clozapine (38). Injection with botulinum toxin is clearly the most effective therapy for oromandibular dystonia (48; 20; 89; 54; 44). In the Dystonia Coalition study, botulinum toxin injections improved symptoms by more than 50% in approximately 80% of subjects (86). The masseter muscles are usually injected in patients with jaw-closure dystonia. Jaw-opening dystonia is more challenging to treat, but injections into the submental muscle complex or the lateral pterygoid muscles usually provide satisfactory relief in most patients (78). In an open trial, a meaningful reduction in the oromandibular-lingual spasms and an improvement in chewing and speech were achieved in more than 70% of treated patients (50). The improvement was noted within an average of 5.5 days after injection and lasted 11.5 weeks. Patients with dystonic jaw closure responded better than those with jaw-opening dystonia. A temporary swallowing problem was noted in less than one-third of patients initially, but this is now a rare complication due to more experience in targeting the appropriate muscles and adjustment in dosages. Although most of our patients with jaw opening oromandibular dystonia benefit from submental injections, patients with jaw protrusion and lateral deviation have been found to have increased contractions of the lateral pterygoid muscles (67). Botulinum toxin injections provide the most effective relief of oromandibular dystonia, and early treatment with botulinum toxin may prevent dental and other complications, including the temporomandibular joint syndrome and other oral and dental problems (10; 52; 98; 99; 100). A systematic review of botulinum toxin studies in oromandibular dystonia involving 387 patients in nine studies showed that the risk of dystonic movements was 39.30% lower in the treatment group compared to the control group (22). Furthermore, a total of 105 of 387 patients (27.1%) experienced adverse events, most commonly dysphagia.

Trismus with or without bruxism may be effectively treated with botulinum toxin into the masseter and temporalis muscles (104; 34; 72; 88). In a study 23 patients with sleep bruxism confirmed by polysomnography were enrolled in a randomized, placebo-controlled, 1:1, parallel-design trial with open-label extension (72). They were injected with a placebo or 200 units of onabotulinumtoxinA (60 into each masseter and 40 into each temporalis) or placebo and were evaluated at 4 to 8 weeks after the initial treatment visit. Clinical global impression and visual analog scale of change favored active treatment. This study provides class two evidence that botulinum injections into the masseter and temporalis muscles improve subjective bruxism and painful symptoms associated with sleep bruxism. Botulinum toxin injections in the tongue can be very effective in patients with oromandibular dystonia and lingual involvement (112).

Botulinum toxin treatment alleviates bruxism and often prevents or alleviates dental complications and temporomandibular joint syndrome (44). Furthermore, it may facilitate the placement of a percutaneous endoscopic gastrostomy tube (79). Oromandibular involuntary movements caused by hemimasticatory spasms and other disorders, such as Satoyoshi syndrome, have also been successfully treated with botulinum toxin (66). Although most patients with oromandibular dystonia continue to benefit from repeat botulinum toxin injections, some develop secondary nonresponsiveness (01). In patients who are resistant to drug or botulinum toxin treatment, muscle spindle afferent block with intramuscular injection of lidocaine and alcohol has been reported to provide an average 70% improvement in patients with jaw-closure dystonia and 38% improvement in jaw-opening dystonia (113). In some patients who were treated for severe generalized dystonia with pallidotomy, there was a marked improvement in oromandibular dystonia (71). Oromandibular dystonia has also been reported to improve with bilateral pallidal deep brain stimulation (18).

Media

References

01: Adler CH, Factor SA, Brin M, Sethi KD. Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia. Mov Disord 2002;17(1):158-61. PMID 11835455
02: Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013;28(7):863-73. PMID 23649720
03: Alonso-Navarro H, Martin-Prieto M, Ruiz-Ezquerro JJ, Jimenez-Jimenez FJ. Bruxism possibly induced by venlafaxine. Clin Neuropharmacol 2009;32(2):111-2. PMID 19512964
04: Baizabal-Carvallo JF, Alonso-Juarez M, Jankovic J. Oromandibular tics associated with Tourette syndrome. J Neurol 2023;270(5):2591-6. PMID 36723683
05: Benecke R, Strumper P, Weiss H. Electron transfer complex-1 defect in idiopathic dystonia. Ann Neurol 1992;32:683-6. PMID 1449249
06: Berardelli A, Rothwell JC, Hallett M, Thompson PD, Manfredi M, Marsden CD. The pathophysiology of primary dystonia. Brain 1998;121:1195-212. PMID 9679773
07: Berman BD, Groth CL, Sillau SH, et al. Risk of spread in adult-onset isolated focal dystonia: a prospective international cohort study. J Neurol Neurosurg Psychiatry 2020;91(3):314-20. PMID 31848221
08: Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 1994;117:859-76. PMID 7922471
09: Black KJ, Ongur D, Perlmutter JS. Putamen volume in idiopathic focal dystonia. Neurology 1998;51:819-24. PMID 9748033
10: Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 1989;98:93-7. PMID 2916831
11: Bonetti M, Barzaghi C, Brancati F. Mutation screening of the DYT6/THAP1 gene in Italy. Mov Disord 2009;24(16):2424-7. PMID 19908325
12: Borie L, Langbour N, Guehl D, Burbaud P, Ella B. Bruxism in craniocervical dystonia: a prospective study. Cranio 2016;34(5):291-5. PMID 26884222
13: Bracha HS, Ralston TC, Williams AE, Yamashita JM, Bracha AS. The clenching-grinding spectrum and fear circuitry disorders: clinical insights from the neuroscience/paleoanthropology interface. CNS Spectr 2005;10:311-8. PMID 15788958
14: Bressman SB, de Leon D, Raymond D, et al. Secondary dystonia and the DYT1 gene. Neurology 1997;48:1571-7. PMID 9191768
15: Bressman SB, Raymond D, Fuchs T, Heiman GA, Ozelius LJ, Saunders-Pullman R. Mutations in THAP1 (DYT6) in early-onset dystonia: a genetic screening study. Lancet Neurol 2009;8(5):441-6. PMID 19345147
16: Britton D, Alty JE, Mannion CJ. Oromandibular dystonia: a diagnosis not to miss. Br J Oral Maxillofac Surg 2020;S0266-4356. PMID 32143935
17: Bucher SF, Seelos KC, Dodel RC, Paulus W, Reiser M, Oertel WH. Pallidal lesions. Structural and functional magnetic resonance imaging. Arch Neurol 1996;53:682-6. PMID 8929177
18: Capelle HH, Weigel R, Krauss JK. Bilateral pallidal stimulation for blepharospasm-oromandibular dystonia (Meige syndrome). Neurology 2003;60(12):2017-8. PMID 12821763
19: Ceballos-Baumann AO, Passingham RE, Marsden CD, Brooks DJ. Motor reorganization in acquired hemidystonia. Ann Neurol 1995;37:746-57. PMID 7778848
20: Colosimo C, Tiple D, Berardelli A. Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: A systematic review. Neurotox Res 2012;22(4):265-73. PMID 22359151
21: Crossman AR, Brotchie JM. Pathophysiology of dystonia. In: Fahn S, Marsden CD, DeLong MR, editors. Dystonia 3, Advances in Neurology, Vol 78. Philadelphia: Lippincott-Raven, 1998:19-25.
22: Dadgardoust PD, Rosales RL, Asuncion RM, Dressler D. Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis. J Neural Transm (Vienna) 2019;126(2):141-8. PMID 30604200
23: Dietrichs E, Heier MS, Nakstad PH. Jaw-opening dystonia presumably caused by a pontine lesion. Mov Disord 2000;15(5):1026-8. PMID 11009222
24: Djarmati A, Schneider SA, Lohmann K, et al. Mutations in THAP1 (DYT6) and generalised dystonia with prominent spasmodic dysphonia: a genetic screening study. Lancet Neurol 2009;8(5):447-52. PMID 19345148
25: Eidelberg D, Moeller JR, Antonini A, et al. Functional brain networks in DYT1 dystonia. Ann Neurol 1998;44:303-12. PMID 9749595
26: Ella B, Ghorayeb I, Burbaud P, Guehl D. Bruxism in Movement Disorders: A Comprehensive Review. J Prosthodont 2017;26(7):599-605. PMID 27077925
27: Esteban A, Traba A, Prieto J, Grandas F. Long term follow up of a hemimasticatory spasm. Acta Neurol Scand 2002;105(1):67-72. PMID 11903113
28: Fahn S, Bressman S, Marsden CD. Classification of dystonia. Adv Neurol 1998;78:1-10. PMID 9750897
29: Farmer SF, Sheean GL, Mayston MJ, et al. Abnormal motor unit synchronization of antagonist muscles underlies pathological co-contraction in upper limb dystonia. Brain 1998;121:801-4. PMID 9619186
30: Fletcher NA, Harding AE, Marsden CD. The relationship between trauma and idiopathic torsion dystonia. J Neurol Neurosurg Psychiatry 1991;54:713-7. PMID 1940944
31: Frucht S, Fahn S, Ford B, Gelb M. A geste antagoniste device to treat jaw-closing dystonia. Mov Disord 1999;14:883-6. PMID 10495062
32: Fuchs T, Gavarini S, Saunders-Pullman R, et al. Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. Nat Genet 2009;41(3):286-8. PMID 19182804
33: Ghadery CM, Kalia LV, Connolly BS. Movement disorders of the mouth: a review of the common phenomenologies. J Neurol 2022;269(11):5812-5830. PMID 35904592
34: Guaita M, Högl B. Current treatments of bruxism. Curr Treat Options Neurol 2016;18(2):10. PMID 26897026
35: Hallett M. Is dystonia a sensory disorder. Ann Neurol 1995;38:139-40. PMID 7654059
36: Hallett M. Physiology of dystonia. Adv Neurol 1998;78:11-8. PMID 9750898
37: Hallett M, Daroff RB. Blepharospasm: report of a workshop. Neurology 1996;46:1213-8. PMID 8628455
38: Hanagasi HA, Bilgic B, Gurvit H, Emre M. Clozapine treatment in oromandibular dystonia. Clin Neuropharmacol 2004;27:84-6. PMID 15252269
39: Handa S, Shaefer JR, Keith DA. Oromandibular dystonia and temporomandibular disorders. J Am Dent Assoc 2022;153(9):899-906. PMID 34863506
40: Houlden H, Schneider SA, Paudel R, et al. THAP1 mutations (DYT6) are an additional cause of early-onset dystonia. Neurology 2010;74(10):846-50. PMID 20211909
41: Ichinose H, Ohye T, Takahashi E, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 1994;8(3):236-42. PMID 7874165
42: Ilic TV, Potter M, Holler I, Deuschl G, Volkmann J. Praying-induced oromandibular dystonia. Mov Disord 2005;20:385-6. PMID 15580567
43: Janavs J, Aminoff MJ. Dystonia and chorea in acquired systemic disorders. J Neurol Neurosurg Psychiatry 1998;65:436-45. PMID 9771763
44: Jankovic J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon 2018;147:84-8. PMID 28888928
45: Jankovic J. Etiology and differential diagnosis of blepharospasm and oromandibular dystonia. In: Jankovic J, Tolosa E, editors. Facial Dyskinesias, Advances in Neurology, Vol 49. New York: Raven Press, 1988:103-16.
46: Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995;18:197-214. PMID 8635179
47: Jankovic J. Can peripheral trauma induce dystonia and other movement disorders? Yes! Mov Disord 2001;16(1):7-12. PMID 11215595
48: Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004;75:951-7. PMID 15201348
49: Jankovic J, Fahn S. Dystonic disorders. In: Jankovic J, Tolosa E, Scott-Conner CE, editors. Parkinson's Disease & Movement Disorders, 4th edition. Philadelphia: Lippincott Williams & Wilkins, 2002:331-57.
50: Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990;53(8):633-9. PMID 2213039
51: Kamphuis DJ, Koelman H, Lees AJ, Tijssen MA. Sporadic rapid-onset dystonia-parkinsonism presenting as Parkinson's disease. Mov Disord 2006;21(1):118-9. PMID 16161139
52: Kanovsky P, Steitova H, Bares H, Hortova H. Treatment of facial and oromandibular tardive dystonia by botulinum toxin A: evidence of a long-lasting effect. Mov Disord 1999;14(5):886-8. PMID 10495063
53: Karbe H, Holthoff VA, Rudolf J, Herholz K, Heiss WD. Positron emission tomography demonstrates frontal cortex and basal ganglia hypometabolism in dystonia. Neurology 1992;42:1540-4. PMID 1641150
54: Karp BI, Alter K. Botulinum toxin treatment of blepharospasm, orofacial/oromandibular dystonia, and hemifacial spasm. Semin Neurol 2016;36(1):84-91. PMID 26866500
55: Klein C, Page CE, LeWitt P, et al. Genetic analysis of three patients with an 18p- syndrome and dystonia. Neurology 1999;52(3):649-51. PMID 10025808
56: Kramer PL, de Leon D, Ozelius L, et al. Dystonia gene in Ashkenazi Jewish population located on chromosome 9q32-34. Ann Neurol 1990;27(2):114-20. PMID 2317008
57: Krystkowiak P, Martinat P, Defebvre L, Pruvo JP, Leys D, Destee A. Dystonia after striatopallidal and thalamic stroke: clinicoradiological correlations and pathophysiological mechanisms. J Neurol Neurosurg Psychiatry 1998;65(5):703-8. PMID 9810942
58: Kwak YT, Han IW, Lee PH, Yoon JK, Suk SH. Associated conditions and clinical significance of awake bruxism. Geriatr Gerontol Int 2009;9(4):382-90. PMID 20002758
59: Kwiatkowski DJ, Nygaard TG, Schuback DE, et al. Identification of a highly polymorphic microsatellite VNTR within the argininosuccinate synthetase locus: exclusion of the dystonia gene on 9q32-34 as a cause of dopa-responsive dystonia in a large kindred. Am J Hum Genet 1991;48(1):121-8. PMID 1985454
60: Lagueny A, Deliac MM, Julien J, Demotes-Mainard J, Ferrer X. Jaw closing spasm--a form of focal dystonia. An electrophysiological study. J Neurol Neurosurg Psychiatry 1989;52(5):652-5. PMID 2732737
61: Lavigne GJ, Khoury S, Abe S, Yamaguchi T, Raphael K. Bruxism physiology and pathology: an overview for clinicians. J Oral Rehabil 2008;35(7):476-94. PMID 18557915
62: Leenders K, Hartvig P, Forsgren L, et al. Striatal [11C]-N-methyl-spiperone binding in patients with focal dystonia (torticollis) using positron emission tomography. J Neural Transm Park Dis Dement Sect 1993;5(2):79-87. PMID 8101445
63: Lehericy S, Vidailhet M, Dormont D, et al. Striatopallidal and thalamic dystonia. A magnetic resonance imaging anatomoclinical study. Arch Neurol 1996;53:241-50. PMID 8651877
64: Ma H, Qu J, Ye L, Shu Y, Qu Q. Blepharospasm, oromandibular dystonia, and Meige syndrome: clinical and genetic update. Front Neurol 2021;12:630221. PMID 33854473
65: Manzo N, Ginatempo F, Belvisi D, et al. Pathophysiological mechanisms of oromandibular dystonia. Clin Neurophysiol 2022;134:73-80. PMID 34979293
66: Merello M, Garcia H, Nogues M, Leiguarda R. Masticatory muscle spasm in a non-Japanese patient with Satoyoshi syndrome successfully treated with botulinum toxin. Mov Disord 1994;9:104-5. PMID 8139588
67: Moller E, Bakke M, Dalager T, Werdelin LM. Oromandibular dystonia involving the lateral pterygoid muscles: four cases with different complexity. Mov Disord 2007;22(6):785-90. PMID 17290453
68: Naumann M, Reiners K. Long-latency reflexes of hand muscles in idiopathic focal dystonia and their modification by botulinum toxin. Brain 1997;120:409-16. PMID 9126053
69: Nutt JG, Muenter MD, Melton J, et al. Epidemiology of dystonia in Rochester, Minnesota. In: Fahn S, Marsden CD, Calne DB, editors. Dystonia, Advances in Neurology, Vol 50. New York: Raven Press, 1988:361-5.
70: Nygaard TG, Takahashi H, Heiman GA, Snow BJ, Fahn S, Calne DB. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia. Ann Neurol 1992;32(5):603-8. PMID 1449240
71: Ondo WG, Desaloms M, Jankovic J, Grossman R. Surgical pallidotomy for the treatment of generalized dystonia. Mov Disord 1998;13:693-8. PMID 9686777
72: Ondo WG, Simmons JH, Shahid MH, Hashem V, Hunter C, Jankovic J. Onabotulinum toxin-A injections for sleep bruxism: a double-blind, placebo-controlled study. Neurology 2018;90(7):e559-64. PMID 29343468
73: Ozelius LJ, Hewett JW, Page CE, et al. The early onset torsion dystonia gene [DYT1] encodes an ATP-binding protein. Nat Genet 1997;17:40-8. PMID 9288096
74: Pandey S, Sharma S. Meige's syndrome: History, epidemiology, clinical features, pathogenesis and treatment. J Neurol Sci 2017;372:162-170. PMID 28017205
75: Perlmutter JS, Stambuk MK, Markham J, et al. Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci 1997;17:843-50. PMID 8987805
76: Pettigrew LC, Jankovic J. Hemidystonia: a report of 22 patients and a review of the literature. J Neurol Neurosurg Psychiatry 1985;48:650-7. PMID 4031909
77: Playford ED, Fletcher NA, Sawle GV, Marsden CD, Brooks DJ. Striatal [18F]dopa uptake in familial idiopathic dystonia. Brain 1993;116:1191-9. PMID 8221055
78: Pons M, Meyer C, Euvrard E, Weber E, Sigaux N, Louvrier A. MR-guided navigation for botulinum toxin injection in the lateral pterygoid muscle. First results in the treatment of temporomandibular joint disorders. J Stomatol Oral Maxillofac Surg 2019;120(3):188-95. PMID 30453102
79: Restivo DA, Maimone D, Patti F, Marchese-Ragona R, Marino G, Pavone A. Trismus after stroke/TBI: botulinum toxin benefit and use pre-PEG placement. Neurology 2005;64(12):2152-3. PMID 15985596
80: Rivest J, Quinn N, Marsden CD. Dystonia in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurology 1990;40:1571-8. PMID 2215950
81: Sankhla C, Lai E, Jankovic J. Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry 1998;65:722-8. PMID 9810945
82: Saraf U, Chandarana M, Divya KP, Krishnan S. Oromandibular dystonia: a systematic review. Ann Indian Acad Neurol 2022;25(1):26-34. PMID 35342238
83: Schapira AH, Warner T, Gash MT, Cleeter MW, Marinho CF, Cooper JM. Complex I function in familial and sporadic dystonia. Ann Neurol 1997;41:556-9. PMID 9124815
84: Schneider S, Feifel E, Ott D, Schumacher M, Lucking CH, Deuschl G. Prolonged MRI T2 times of the lentiform nucleus in idiopathic spasmodic torticollis. Neurology 1994;44:846-50. PMID 8190286
85: Scorr LM, Cho HJ, Kilic-Berkmen G, et al. Clinical features and evolution of blepharospasm: a multicenter international cohort and systematic literature review. Dystonia 2022;1:10359. PMID 36248010
86: Scorr LM, Factor SA, Parra SP, et al. Oromandibular dystonia: a clinical examination of 2,020 cases. Front Neurol 2021;12:700714. PMID 34603182
87: Scrivani SJ, Keith DA, Kaban LB. Temporomandibular disorders. N Engl J Med 2008;359(25):2693-705. PMID 19092154
88: Sendra LA, Azeredo Alves Antunes L, Barboza EP. Use of botulinum neurotoxin Type A in the management of primary bruxism in adults: an updated systematic review. J Prosthet Dent 2022;S0022-3913(22)00331-6. PMID 35779974
89: Sinclair CF, Gurey LE, Blitzer A. Oromandibular dystonia: long-term management with botulinum toxin. Laryngoscope 2013;123(12):3078-83. PMID 24122897
90: Singer C, Papapetropoulos S. A comparison of jaw-closing and jaw-opening idiopathic oromandibular dystonia. Parkinsonism Relat Disord 2006;12(2):115-8. PMID 16271495
91: Slaim L, Cohen M, Klap P, et al. Oromandibular dystonia: demographics and clinical data from 240 patients. J Mov Disord 2018;11(2):78-81. PMID 29860784
92: Steinberger D, Weber Y, Korinthenberg R, et al. High penetrance and pronounced variation in expressivity of GCH1 mutations in five families with dopa-responsive dystonia. Ann Neurol 1998;43:634-9. PMID 9585358
93: Stremmel W, Meyerrose KW, Niederau C, Hefter H, Kreuzpaintner G, Strohmeyer G. Wilson disease: clinical presentation, treatment, and survival. Ann Int Med 1991;115:720-6. PMID 1929042
94: Sude A, Matsumoto J, Kaimal S, Petersen A, Nixdorf DR. Temporomandibular disorder-related characteristics and treatment outcomes in oromandibular dystonia patients in two different clinical settings: a cross-sectional study. J Oral Rehabil 2021;48(5):542-50. PMID 33682178
95: Svetel M, Kozić D, Stefanova E, Semnic R, Dragasevic N, Kostic VS. Dystonia in Wilson’s disease. Mov Disord 2001;16:719-23. PMID 11481698
96: Tan EK, Chan LL, Chang HM. Severe bruxism following basal ganglia infarcts: insights into pathophysiology. J Neurol Sci 2004;217(2):229-32. PMID 14706229
97: Tan EK, Jankovic J. Bilateral hemifacial spasm: a report of 5 cases and a literature review. Mov Disord 1999a;14:345-9. PMID 10091632
98: Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 1999b;53:2102-5. PMID 10599789
99: Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. JADA 2000a;131:211-6. PMID 10680389
100: Tan EK, Jankovic J. Bruxism in Huntington’s disease. Mov Disord 2000b;15:171-3. PMID 10634263
101: Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry 2000c;68:186-90. PMID 10644785
102: Tee TY, Khoo CS, Norlinah MI. Prominent oromandibular dystonia as levodopa-induced dyskinesia in idiopathic Parkinson's disease. Mov Disord Clin Pract 2019;6(4):330-1. PMID 31061844
103: Thompson PD, Obeso JA, Delgado G, et al. Focal dystonia of the jaw and the affirmative diagnosis of unilateral jaw and masticatory spasm. J Neurol Neurosurg Psychiatry 1986;49:651-65. PMID 3734821
104: Tinastepe N, Küçük BB, Oral K. Botulinum toxin for the treatment of bruxism. Cranio 2015;33(4):291-8. PMID 26715152
105: Tokiwa O, Park BK, Takezawa Y, Takahashi Y, Sasaguri K, Sato S. Relationship of tooth grinding pattern during sleep bruxism and dental status. Cranio 2008;26(4):287-93. PMID 19004310
106: Valente EM, Bentivoglio AR, Cassetta E, et al. DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13-36.32 in an Italian family with cranial-cervical or upper limb onset. Ann Neurol 2001;49(3):362-6. PMID 11261511
107: Vitek JL, Zhang J, Evatt M, et al. GPi pallidotomy for dystonia: clinical outcome and neuronal activity. In: Fahn S, Marsden CD, DeLong DR, editors. Dystonia 3, Advances in Neurology, Vol 78. Philadelphia: Lippincott- Raven, 1998:211-9.
108: Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) 2013;3. PMID 23858394
109: Wang A, Jankovic J. Hemifacial spasm: clinical correlates and treatments. Muscle Nerve 1998;21:1740-7. PMID 9843077
110: Watts MW, Tan EK, Jankovic J. Bruxism and cranial-cervical dystonia: is there a relationship. Cranio 1999;17(3):196-201. PMID 10650407
111: Yaltho TC, Jankovic J. The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord 2011;26(9):1582-92. PMID 21469208
112: Yoshida K. Botulinum neurotoxin therapy for lingual dystonia using an individualized injection method based on clinical features. Toxins (Basel) 2019;11(1):51. PMID 30658420
113: Yoshida K, Kaji R, Kubori T, et al. Muscle afferent block for the treatment of oromandibular dystonia. Mov Disord 1998;13:699-705. PMID 9686778

Patient Profile

Age range of presentation: 19 to 65+ years
Sex preponderance: male=female
Heredity: heredity may be a factor
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Orofacial dyskinesia: 333.82

Isolated oromandibular dystonia: 333.82

Genetic torsion dystonia: 333.6
ICD-10: Idiopathic orofacial dystonia: G24.4

Isolated oromandibular dystonia: G24.42

Ocular dystonia, nonfamilial: G24.230

Other cranial dystonia, nonfamilial: G24.23

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Oromandibular dystonia

Associated Disorders

Basal ganglia infarcts
Brainstem lesions
Dystonia
Huntington disease
Neuroacanthocytosis
- Temporomandibular joint syndrome

Differential Diagnosis

tetany
tetanus
trismus
mechanical disorder of the jaw
mechanical disorder of the temporomandibular joint
- other facial movement disorders
- hemifacial spasm
- facial tics
- myokymia
- myorhythmia
- hemimasticatory spasm
- aberrant regeneration with synkinesis after Bell palsy
- bilateral hemifacial spasm
- tic convulsif

Also Relevant

Blepharospasm
Botulinum toxin treatment of neurologic disorders
Childhood movement disorders
Hemifacial spasm
Rating scales of movement disorders
- Sleep bruxism

Oromandibular dystonia …

Oromandibular dystonia

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Table 1. Etiology of Blepharospasm and Oromandibular Dystonia

Diagnostic workup

Management

Media

References

Contributors

Author

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

Sleep-related leg cramps

Sleep and cerebral degenerative disorders

Oromandibular dystonia

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Table 1. Etiology of Blepharospasm and Oromandibular Dystonia

Diagnostic workup

Management

Media

References

Contributors

Author

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

Sleep-related leg cramps

Sleep and cerebral degenerative disorders

This is an article preview.
Start a Free Account
to access the full version.